David J Harnick, MD

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Scopus h-index:7

Article:9

Recent Artifacts

• Frequency and outcomes of reduced dose Non-Vitamin K antagonist anticoagulants: Results from ORBIT-AF II (The outcomes registry for better informed treatment of atrial fibrillation II)
• Reverse electrical remodeling of the atria post cardioversion in patients who remain in sinus rhythm assessed by signal averaging of the P-wave
• Electrophysiologic interventions in patients with inferior vena cava filters: Safety and efficacy of the transfemoral approach
• Spontaneous echo contrast videodensity is flow-related and is dependent on the relative concentrations of fibrinogen and red blood cells
• Comparison of physician-managed lipid-lowering care in patients with coronary heart disease in two time periods (1994 and 1999)
• Platelet glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: Initiate treatment early or wait for the catheterization laboratory?
• Effects of practice setting on quality of lipid-lowering managementin patients with coronary artery disease
• The inositol 1,4,5-trisphosphate receptor is essential for T-cell receptor signaling
• The human type 1 inositol 1,4,5-trisphosphate receptor from T lymphocytes: Structure, localization, and tyrosine phosphorylation

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Harnick has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.